Novartis says profit up 15% in 2017

January 24, 2018
Novartis said it had 'a good year' in 2017

Swiss pharmaceuticals giant Novartis said Wednesday that strong sales of two of its main blockbuster drugs enabled it to turn in a "good operational performance" in 2017.

Novartis said in a statement that climbed by 15 percent to $7.7 billion in 2017 on a one-percent increase in sales to $49.1 billion.

"Novartis had a good year in 2017," said chief executive Joe Jimenez.

The group's psoriasis drug, Cosentyx, "reached multi-blockbuster status," the heart treatment Entresto delivered more than $500 million in sales and the eye care unit Alcon "returned to growth," the statement said.

Underlying or operating of $12.9 billion was "broadly in line with prior year as sales growth and productivity fully offset generic erosion and growth investments," Novartis said.

Looking ahead, "barring unforeseen events, group net sales in 2018 are expected to grow low to mid single digit," Novartis said.

And underlying profit was expected "to grow mid to high single digit," it added.

"With several key launches on the horizon and our new operating model in place, Novartis is poised for sustainable ," said CEO Jimenez.

Explore further: Novartis sees bright future for eye unit

Related Stories

Novartis sees bright future for eye unit

October 24, 2017

Swiss pharmaceutical giant Novartis said Tuesday a strategic review of its eye care unit showed that Alcon can deliver strong growth, but that a possible spin-off or listing is at least two years away.

Novartis to buy back $5 bn in shares

January 25, 2017

Swiss pharmaceutical giant Novartis announced Wednesday a $5.0 billion share buyback even though competition from generics ate away at sales and earnings last year.

Generic medicines hit Novartis profits

July 18, 2017

Swiss drugmaker Novartis on Tuesday posted a drop in first half profits amid fierce competition for generic medicines and pricing pressures but said it was set to reach annual targets.

Novartis Q4 net profit rises to $2.0 billion

January 29, 2014

Swiss drug maker Novartis AG reported a 2 percent rise in fourth-quarter net profit Wednesday, helped by delays in generic competition to its blockbuster drugs.

Novartis profit slips as key drug goes generic

October 25, 2016

Swiss drug company Novartis saw net profit slip in the third quarter as the loss of a key drug to generic use in the United States outweighed strong sales of its psoriasis drug Cosentyx and MS treatment Gilenya.

Recommended for you

Inert nitrogen forced to react with itself

March 21, 2019

Constituting over 78 % of the air we breathe, nitrogen is the element found the most often in its pure form on earth. The reason for the abundance of elemental nitrogen is the incredible stability and inertness of dinitrogen ...

Two-step path to shrinking worker bee gonads

March 21, 2019

The dramatic difference in gonad size between honey bee queens and their female workers in response to their distinct diets requires the switching on of a specific genetic program, according to a new study publishing March ...

Plant immunity cut to size

March 21, 2019

An international team based in Ghent, Belgium (VIB-UGent Center for Plant Systems Biology) and Basel, Switzerland (University of Basel), found a link between a class of enzymes and immune signals that is rapidly triggered ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.